Evidence map›Paper›PMID 36145679›Full record

ReviewPharmaceutics2022

Ocular Drug Delivery: Advancements and Innovations.

Bo Tian, Evan Bilsbury, Sean Doherty, Sean Teebagy, Emma Wood, Wenqi Su, Guangping Gao, Haijiang Lin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bo Tian *Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.ORCID 0000-0002-9910-535X
Evan Bilsbury *Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Sean DohertyDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Sean TeebagyDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Emma WoodDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.ORCID 0000-0003-1551-7793
Wenqi SuDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Haijiang LinDepartment of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of "drug delivery" for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.

Indexed as

adeno-associated virusadministration routesgene therapymedication carriersnon-viral vectorsocular drug delivery

Identifiers

PMID36145679
PMCPMC9506479

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.